20 articles
Mitochondria-targeted antioxidant polymer shows superior protection against liver transplant injury compared to standard treatments.
NO-primed extracellular vesicles transfer functional mitochondria to damaged kidney cells, restoring energy production and reducing injury.
New research explores using Klotho protein with stem cell-derived vesicles to treat acute kidney injury, potentially offering regenerative therapy.
Wave Life Sciences shares early trial data on an RNA editing treatment for alpha-1 antitrypsin deficiency, targeting monthly dosing.
Single-cell sequencing reveals ferroptosis drives pulpitis; thymosin α1 restores GPX4, cuts iron overload, and reduces inflammation in cells and rats.
Novel nanogel therapy targets mitochondrial ROS to break the inflammation-hypoxia cycle in periodontitis, showing strong preclinical results.
Dasatinib + quercetin clears senescent kidney cells, restores anti-aging protein Klotho, and reverses transcriptional aging across multiple renal cell types.
Scientists develop first drug targeting AVIL protein, showing effectiveness against deadly glioblastoma tumors in preclinical trials.
A new class of drugs called proximity degraders can destroy disease-causing proteins once considered untreatable. Here's what's coming next.
A phase 1 dose-escalation trial tests the safety of AAV-delivered ND4 gene therapy in patients with Leber's hereditary optic neuropathy.
Arvinas' vepdegestrant becomes the first PROTAC to clear Phase 3 trials, targeting disease proteins for destruction rather than just blocking them.
AAV gene therapy successfully restored retinal function and improved vision in rats with LRAT-associated retinitis pigmentosa.
Single injection of protective brain protein via gene therapy fully restored memory formation and dramatically reduced amyloid plaques.
New research explores how naturally occurring aldehydes in our bodies might trigger clonal hematopoiesis, a blood disorder linked to aging.
New research shows GDF11 protein can prevent and treat steroid-induced bone death by activating blood vessel formation pathways.
Scientists discover how plant compounds enhance stem cell therapy for kidney disease through improved cellular messaging.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
Researchers used prime editing to introduce and then correct a de novo GDF11 nonsense mutation, revealing Golgi stress and broad transcriptomic dysregulation.
A 4-year follow-up of a phase 2 trial finds autologous macrophage therapy nearly halves death or transplant rates in liver cirrhosis.
Dihydrotestosterone treatment restored heart function in aging mice by activating DNA repair mechanisms and reducing inflammation.
